3 March 11th, Shuangcheng Pharmaceutical (002693) showed abnormal movement at 09:36 in the morning trading today. As of press time, Shuangcheng Pharmaceutical was 5.68 yuan per share, an increase of 10.08%, a trading volume of 214,000 lots, a turnover rate of 5.31%, an amplitude of 5.81%, and a volume ratio of 7.07.
Technical aspect, Shuangcheng Pharmaceutical (002693) is currently on the 5-day, 10-day, 20-day and 30-day lines. In addition, the short-term moving average of the stock has a clear "bang arrangement", and there is a strong bullish signal in technology. The latest interim report of
shows that Shuangcheng Pharmaceutical (002693) achieved operating income of 259101282.37, net profit loss of 32452000, a year-on-year decrease of 237.32%, and earnings per share -0.08. The pharmaceutical and biological industry where
Shuangcheng Pharmaceutical (002693) is located has an overall decline of 100.00%. Individual stocks in the sector, N Ogilvy (002950), Shuangcheng Pharmaceutical (002693), and Jimin Pharmaceutical (603222) rose significantly, up 43.97%, 10.08%, and 10.02% respectively; Longjin Pharmaceutical (002750), Qidi Guhan (000590), and Changchun Hi-Tech (000661) increased significantly, with a volume ratio of 142.54, 18.17, and 18.1 respectively; related stocks with larger amplitudes include N Ogilvy (002950), Shanghai Laish (002252), and Zixin Pharmaceutical (002118), with amplitudes of 23.93%, 19.05%, respectively, 11.63%;
Shuangcheng Pharmaceutical (002693) is mainly engaged in the research, development, production and sales of chemical synthetic polypeptide drugs. The third quarter report shows that the company's number of shareholders (households) was 38,400, a decrease of 7.09% from the previous reporting period.
Hainan Shuangcheng Pharmaceutical Co., Ltd. has been engaged in the research, development, production and sales of chemical synthetic polypeptide drugs since its establishment. It has become one of the key backbone enterprises in my country's chemical synthetic polypeptide industry. The company's leading product, Thymus For Injection (trade name "Jitai"), is the second domestic brand to be listed in China. It was recognized as a provincial high-tech project by the Hainan Provincial Department of Science and Technology in 2001 and was included in the National Torch Plan by the Ministry of Science and Technology in 2004. Thymus For Injection has entered the 2009 edition of the "Medical Insurance Catalog" and the 2010 edition of the "Chinese Pharmacopoeia", and was included in the tumor list by the 2010 edition of the "China National Prescription Collection". It is also the only non-specific immunomodulator recommended in the immunomodulatory treatment of "China Chronic Hepatitis B Prevention and Treatment Guidelines (2010)" and "Asia-Pacific Chronic Hepatitis B Management Consensus (2008)".
